Vita 34 AG strengthens its international brand presence by change of name to FamiCord AG

• Change of name on the basis of the Group's internationally most recognized brand name
• Vita 34 to be continued as very well-established brand in end customer business mostly in the DACH region
• Comprehensive Group integration and structure simplification proceed as planned

Leipzig, 6 February 2025 – Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), the leading cell bank in Europe and the third largest worldwide, is now operating under the name FamiCord AG. By changing its name, the Group is positioning its most widely used brand even more clearly and successfully completing an important step for its further international growth.

“By changing our name to FamiCord, we are placing our internationally most recognized brand even more clearly in the foreground. This step is an important milestone for our further international growth and expansion into other business segments”, emphasizes Jakub Baran, CEO of FamiCord AG. “Vita 34 will remain with us as an established brand in the end customer business. For our customers and business partners in the DACH region, this step will therefore not change much, and the familiar contact details will also remain unchanged.”

FamiCord's brand strategy involves the use of different consumer brands in different markets. The Vita 34 brand will continue to operate mainly in the German, Austrian and Swiss markets. The renaming on the Group level, however, reflects the continuous growth of the Company both in current and in new markets as well as in new business segments. “The FamiCord brand is widely used as an umbrella brand in more than 30 markets in Europe and beyond. Local brands use the 'FamiCord Group Member' endorsement in their logo and communications to highlight the fact that they are part of the leading healthcare provider in the field of family stem cell banking”, explains Tomasz Baran, CCO of FamiCord AG.

In addition to the purely legal name change, the Company has also relaunched its website. In addition to an even more comprehensive range of information for new and existing customers, FamiCord also offers investors an even more transparent presence in the area of investor relations. “It was important to us to strengthen our capital market communication with an even clearer visual and unified appearance,” explains Thomas Pfaadt, CFO of FamiCord AG. “For example, we are planning to make the recordings of our regular video conferences for institutional investors available on our website in future in order to interest even more investors in our equity story.”

Further information on FamiCord and its affiliated subsidiaries can be found at .

Contact: 
FamiCord AG
Investor Relations
Phone: +49 (0341) 487920
Email:

Company profile

FamiCord (formerly Vita 34) was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since offered the collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service provider for cryopreservation. The donor's own cells are a valuable starting material for medical cell therapy and are kept alive in the vapor of liquid nitrogen. Customers from about 50 countries have already provided for the health of their families with about one million units of stored biological material at FamiCord. Furthermore, the Company is active in the areas of Cell & Gene therapies and CDMO.